Clinical characteristics and risk factors for escalation to anaphylaxis from non-severe drug hypersensitivity reaction

IF 4.6 2区 医学 Q2 ALLERGY
Hyo-In Rhyou, Sung-Ryeol Kim, Jae-Woo Jung, Sae-Hoon Kim, Ji-Hyang Lee, Hye Jung Park, Kyung-Hee Park, Hee-Sun Park, Eun-Hee Chung, Gil-Soon Choi, Sujeong Kim, Min-Suk Yang, Jung-Yeon Shim, Young-Il Koh, Da-Woon Sim, Jae-Hyun Lee, Young-Hee Nam, Hye-Ryun Kang
{"title":"Clinical characteristics and risk factors for escalation to anaphylaxis from non-severe drug hypersensitivity reaction","authors":"Hyo-In Rhyou,&nbsp;Sung-Ryeol Kim,&nbsp;Jae-Woo Jung,&nbsp;Sae-Hoon Kim,&nbsp;Ji-Hyang Lee,&nbsp;Hye Jung Park,&nbsp;Kyung-Hee Park,&nbsp;Hee-Sun Park,&nbsp;Eun-Hee Chung,&nbsp;Gil-Soon Choi,&nbsp;Sujeong Kim,&nbsp;Min-Suk Yang,&nbsp;Jung-Yeon Shim,&nbsp;Young-Il Koh,&nbsp;Da-Woon Sim,&nbsp;Jae-Hyun Lee,&nbsp;Young-Hee Nam,&nbsp;Hye-Ryun Kang","doi":"10.1002/clt2.70047","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Drug hypersensitivity reaction (DHR) poses significant challenges in clinical practice, with some patients experiencing more severe reactions upon re-exposure. Understanding the factors contributing to escalation into more severe reactions is crucial for improving patient safety. This study aimed to investigate the clinical characteristics and risk factors associated with the progression from non-severe DHR to anaphylaxis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A multicenter retrospective study was conducted using data from a drug-induced anaphylaxis registry across 10 university hospitals in Korea. Clinical data, including information on culprit drugs, DHR history, and the severity of reactions, were assessed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 494 cases of drug-induced anaphylaxis, 417 cases (84.4%) occurred without prior DHR, while 77 cases (15.6%) had a history of non-severe DHR. Of these, 43 cases had a previous DHR to a drug of the same class, and 34 cases involved DHR to drugs of different classes. In the group with prior DHR to a drug of the same class, anaphylaxis occurring in daily life was significantly more common compared to those reacting to a different class of drug or those with no prior DHR (48.8% vs. 23.5% or 22.5%, <i>p</i> = 0.008 and &lt; 0.001, respectively). Non-steroidal anti-inflammatory drugs (NSAIDs), H2 blockers, and penicillins were identified as risk factors for anaphylaxis evolving from non-severe DHR.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Enhanced vigilance is required for patients with a history of non-severe DHR to NSAIDs, H2 blockers, and penicillins as re-exposure may lead to the progress to anaphylaxis.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 4","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70047","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.70047","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Drug hypersensitivity reaction (DHR) poses significant challenges in clinical practice, with some patients experiencing more severe reactions upon re-exposure. Understanding the factors contributing to escalation into more severe reactions is crucial for improving patient safety. This study aimed to investigate the clinical characteristics and risk factors associated with the progression from non-severe DHR to anaphylaxis.

Methods

A multicenter retrospective study was conducted using data from a drug-induced anaphylaxis registry across 10 university hospitals in Korea. Clinical data, including information on culprit drugs, DHR history, and the severity of reactions, were assessed.

Results

Among 494 cases of drug-induced anaphylaxis, 417 cases (84.4%) occurred without prior DHR, while 77 cases (15.6%) had a history of non-severe DHR. Of these, 43 cases had a previous DHR to a drug of the same class, and 34 cases involved DHR to drugs of different classes. In the group with prior DHR to a drug of the same class, anaphylaxis occurring in daily life was significantly more common compared to those reacting to a different class of drug or those with no prior DHR (48.8% vs. 23.5% or 22.5%, p = 0.008 and < 0.001, respectively). Non-steroidal anti-inflammatory drugs (NSAIDs), H2 blockers, and penicillins were identified as risk factors for anaphylaxis evolving from non-severe DHR.

Conclusion

Enhanced vigilance is required for patients with a history of non-severe DHR to NSAIDs, H2 blockers, and penicillins as re-exposure may lead to the progress to anaphylaxis.

Abstract Image

非严重药物超敏反应升级为过敏反应的临床特征和危险因素
药物超敏反应(DHR)在临床实践中是一个重大挑战,一些患者在再次接触后会出现更严重的反应。了解导致病情升级为更严重反应的因素对于提高患者安全至关重要。本研究旨在探讨从非严重DHR发展为过敏反应的临床特征和危险因素。方法采用韩国10所大学医院的药物性过敏反应登记数据进行多中心回顾性研究。评估临床数据,包括罪魁祸首药物信息、DHR史和反应严重程度。结果494例药物性过敏反应中,417例(84.4%)无DHR史,77例(15.6%)有非严重DHR史。其中,43例既往对同类药物有DHR, 34例对不同类别药物有DHR。在既往对同类药物有DHR的组中,日常生活中发生过敏反应的发生率明显高于对不同类别药物有反应的组或既往无DHR的组(48.8%比23.5%或22.5%,p = 0.008和<;分别为0.001)。非甾体抗炎药(NSAIDs)、H2阻滞剂和青霉素类药物被确定为非严重DHR演变为过敏反应的危险因素。结论有非严重DHR史的患者应提高对非甾体抗炎药、H2阻滞剂和青霉素类药物的警惕,再次暴露可能导致过敏反应的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Translational Allergy
Clinical and Translational Allergy Immunology and Microbiology-Immunology
CiteScore
7.50
自引率
4.50%
发文量
117
审稿时长
12 weeks
期刊介绍: Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信